Bristol-Myers Squibb said Thursday it has reached an agreement with Merck & Co. to end their collaboration on Pargluva (muraglitazar), an investigational oral drug for the treatment of type 2 diabetes.
Under the mutually brokered agreement, all rights to the drug return to Bristol-Myers Squibb. The deal also covers the reversion to Bristol-Myers of a back-up compound to muraglitazar.
Bristol-Myers said it is considering a range of options on how to best proceed with the diabetes treatment, including conducting additional studies or terminating further development of the drug.
Insider says: Pargluva is a dead duck! Go here to find out why:
http://pharmagossip.blogspot.com/2005/11/pargluva-illusion-of-safety.html
No comments:
Post a Comment